Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0249655 http://scihub22266oqcxt.onion/10.1371/journal.pone.0249655 33983981!8118515!33983981     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33983981&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       PLoS+One 2021 ; 16 (5): e0249655 Nephropedia Template TP {{tp|p=33983981|t=2021. Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan |pdf=|usr=}}{{33983981}} gab.com Text Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=33983981 #FOAvip Moderate cases account for the majority in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients. The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan. A total of 73 moderate patients (38 men, 35 women) were included, with median age of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough, fever, chest tightness, and fatigue were 11.0, 8.0, 11.0, and 7.0 days, respectively; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was 16.5 days; the median hospitalization time was 25.0 days in 72 moderate survivors. The duration of cough and fever was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia; less than 30% had abnormal blood biochemistry findings involving hyperglycemia, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence of the positive NAT results. Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. A small proportion of the recovered moderate patients still may be virus carriers and require an additional round of viral detection. Twit Text FOAVip Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=33983981 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33983981 #FOAvip English Wikipedia <ref>{{Cite pmid|33983981}}</ref> Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan #MMPMID33983981 Peng X; Liu Q; Chen Z; Wen G; Li Q; Chen Y; Xiong J; Meng X; Ding Y; Shi Y; Tang S PLoS One 2021[]; 16 (5): e0249655 PMID33983981show ga Moderate cases account for the majority in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients. The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan. A total of 73 moderate patients (38 men, 35 women) were included, with median age of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough, fever, chest tightness, and fatigue were 11.0, 8.0, 11.0, and 7.0 days, respectively; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was 16.5 days; the median hospitalization time was 25.0 days in 72 moderate survivors. The duration of cough and fever was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia; less than 30% had abnormal blood biochemistry findings involving hyperglycemia, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence of the positive NAT results. Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. A small proportion of the recovered moderate patients still may be virus carriers and require an additional round of viral detection. |Adult[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19/blood/*diagnosis/epidemiology/*therapy[MESH] |China/epidemiology[MESH] |Disease Management[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Hospitalization[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH]Clinical course and management of 73 hospitalized moderate patients wi(epmc).pdf DeepDyve Pubget Overpricing